Monograph Details
|
|
Dermatological Disorders
> Psoriasis
|
|
TACLONEX |
| Manufacturer |
|
Warner Chilcott Laboratories |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Vit. D3 derivative + topical steroid. |
| Generic Name |
|
Calcipotriene (as hydrate) 0.005% + betamethasone dipropionate 0.064%; oint. |
| Also |
|
• TACLONEX SCALP
|
| Indications |
|
Plaque psoriasis. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
≥18yrs: apply to affected area once daily for up to 4 weeks; max 100g/wk. Limit treatment area to 30% body surface area. Do not occlude. |
| Contraindications |
|
Oint: disorders of calcium metabolism. Do not use for erythrodermic, exfoliative, or pustular psoriasis. Oint and Scalp: Do not use on face, axillae, groin, or atrophic skin. |
| Precautions |
|
Avoid eyes, sun, UV light (eg, phototherapy). Discontinue if hypercalcemia, HPA axis suppression, Cushing's syndrome, hyperglycemia, glucosuria, or irritation occurs. Treat infection if present. Severe renal or hepatic dysfunction. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Systemic absorption potentiated by other corticosteroids. |
| Adverse Reactions |
|
Local effects (eg, pruritus, rash, burning, atrophy, skin hypopigmentation or hyperpigmentation, erythema, telangiectasia, contact dermatitis, folliculitis, pustular psoriasis); hypercalcemia, HPA axis suppression (esp. in children). |
| How Supplied |
Oint—60g, 100g
Susp—15g, 30g, 60g, 120g (2x60g) |
|
|
|
|
